Beijing, China, September 6, 2023 – Recently, China's first modular surgical robot, Carina™ RAS Platform, completed its first-in-human clinical trial (FIM), marking a groundbreaking achievement by Ronovo Surgical, a pioneering innovator in the field of Chinese robotic-assisted laparoscopic surgery.
Ronovo Surgical's independent research and development of this innovative product, Carina™ RAS Platform, with proprietary intellectual property, has disrupted the monopoly of integrated surgical robots from foreign countries. The successful implementation of domestically produced modular surgical robots represents a milestone in the Chinese surgical robot industry.
Source: Ronovo Surgical
Regarding the successful completion of the FIM, Professor Ye Dingwei, Chairman of the Urinary Male Reproductive Tumor Special Committee of the Chinese Anti-Cancer Association, Vice President of the Fudan University Shanghai Cancer Center, and renowned urology expert, praised, "The modular surgical robot fully leverages the advantages of robotic surgical systems. Its operation system is simple and efficient, and the mechanical arms are nimble and highly precise. This greatly enhances the operability of robot-assisted surgeries for urinary system tumors, marking a significant step forward for domestically produced robot platforms."
About Ronovo Surgical
In 2019, a group of medtech industry veterans and robotic surgery experts in China and US came together to launch Ronovo Surgical in the bustling global innovation hub of Shanghai. In just three years, the team had filed 50+ patents – 80% invention patents and 20% already granted. With a deep bench of R&D experts and agile global partnership capability, Ronovo has accelerated the development of digital and robotic solutions for MIS, poised to empower traditional ORs with simplicity, precision and intelligence.
For more information, please visit: https://www.ronovosurgical.com/
Comments